retatrutide safety 📊 RETATRUTIDE: THE TRIPLE ACTION APPROACH Want to understand what makes different from other GLP-1 medications? Here's the breakdown: • GLP-1 pathway: Reduces appetite & improves insulin sensitivity • GIP pathway retatrutide safety profile clinical trials

On June 25, 2024, at the 2024 American Diabetes Association (ADA) Scientific Sessions, Suzhou Innovent Biologics and Eli Lilly announced the results of a Phase 3 clinical trialfor the GLP-1R x GCGR dual agonist, Mazdutide

While reducing food intake, these drugs do not necessarily promote healthy, quality food intake, which is necessary for optimal metabolic health on the cellular level

In fact, there is a strong correlation in the level of glycated Lp(a) and the severity of hyperglycemia observed in poorly controlled type 2 diabetes

Presented for research literature review only Forloni G et al

Garner, A

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits fat formation without affecting blood sugar or IGF-1 levels